Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Shortage: Vaccine Worries
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-03-01-2001
Volume 0
Issue 0
United States-At this time last year, the United States} supply of tetanus vaccine was easily met by the two companies licensed to produce it there, Aventis Pasteur and Wyeth-Ayerst. But in June 2000, the latter ran into regulatory problems, and FDA seized thousands of substandard doses of acellular pertussis vaccine from the company}s Marietta, Pennsylvania, plant.
Articles in this issue
Research: New Horizons
The Challenge of Prescription Drug Pricing
Earnings: Tough Times Ahead
Antigenics: Quest for a Cure
Outbreak: Anthrax Alarm
Patents: China on the Genome Map
Privacy, Pediatrics, and Policy
Lilly's International Family
Update: Punishment and Reprieve
Biotech: Down for the Count
Shortage: Vaccine Worries
Access: Success Story
Gateway to Japan
Surrounded
Recent Videos
Related Content
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Podcast
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
